Display options
Cite
duPont NC, Enserro D, Brady MF, et al. Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2021;doi: 10.1016/j.ygyno.2021.11.013.
duPont, N. C., Enserro, D., Brady, M. F., Moxley, K., Walker, J. L., Cosgrove, C., Bixel, K., Tewari, K. S., Thaker, P., Wahner Hendrickson, A. E., Rubin, S., Fujiwara, K., Casey, A. C., Soper, J., Burger, R. A., & Monk, B. J. (2021). Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study. Gynecologic oncology, . https://doi.org/10.1016/j.ygyno.2021.11.013
duPont, Nefertiti C, et al. "Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study." Gynecologic oncology vol. (2021). doi: https://doi.org/10.1016/j.ygyno.2021.11.013
duPont NC, Enserro D, Brady MF, Moxley K, Walker JL, Cosgrove C, Bixel K, Tewari KS, Thaker P, Wahner Hendrickson AE, Rubin S, Fujiwara K, Casey AC, Soper J, Burger RA, Monk BJ. Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2021 Nov 29; doi: 10.1016/j.ygyno.2021.11.013. Epub 2021 Nov 29. PMID: 34857397.
Copy Download .nbib Format: NLM
Share it on

Gynecol Oncol. 2021 Nov 29; doi: 10.1016/j.ygyno.2021.11.013. Epub 2021 Nov 29.

Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.

Gynecologic oncology

Nefertiti C duPont, Danielle Enserro, Mark F Brady, Katherine Moxley, Joan L Walker, Casey Cosgrove, Kristin Bixel, Krishnansu S Tewari, Premal Thaker, Andrea E Wahner Hendrickson, Stephen Rubin, Keiichi Fujiwara, A Catherine Casey, John Soper, Robert A Burger, Bradley J Monk

Affiliations

  1. North Houston Gynecologic Oncology Surgeons, Shenandoah, TX, USA. Electronic address: [email protected].
  2. NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Electronic address: [email protected].
  3. NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Electronic address: [email protected].
  4. University of Oklahoma, Oklahoma University Hospital Science Center, Oklahoma City, OK 73104, USA. Electronic address: [email protected].
  5. University of Oklahoma, Oklahoma University Hospital Science Center, Oklahoma City, OK 73104, USA. Electronic address: [email protected].
  6. Ohio State University Medical Center, USA. Electronic address: [email protected].
  7. Ohio State University Medical Center, USA. Electronic address: [email protected].
  8. University of California at Irvine, Orange, CA 92868, USA. Electronic address: [email protected].
  9. Washington University, Saint Louis, MO 63110, USA. Electronic address: [email protected].
  10. Mayo Clinic, Rochester, MN 55905, USA. Electronic address: [email protected].
  11. Abramson Cancer Center at University of Pennsylvania, Philadelphia, PA 19111, USA. Electronic address: [email protected].
  12. Saitama Medical University/International Medical Center, Saitama, JP 350-1298, Japan. Electronic address: [email protected].
  13. Metro Minn CCOP, Minneapolis, MN, USA. Electronic address: [email protected].
  14. University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: [email protected].
  15. Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), Phoenix, AZ, USA. Electronic address: [email protected].
  16. University of Arizona College of Medicine, Phoenix Creighton University School of Medicine at St. Joseph's Hospital, Phoenix, AZ, USA. Electronic address: [email protected].

PMID: 34857397 DOI: 10.1016/j.ygyno.2021.11.013

Abstract

BACKGROUND: Age and ethnicity are among several factors that influence overall survival (OS) in ovarian cancer. The study objective was to determine whether ethnicity and age were of prognostic significance in women enrolled in a clinical trial evaluating the addition of bevacizumab to front-line therapy.

METHODS: Women with advanced stage ovarian, primary peritoneal, or fallopian tube cancer were enrolled in a phase III clinical trial. All women had surgical staging and received adjuvant chemotherapy with one of three regimens. Cox proportional hazards models were used to evaluate the relationship between OS with age and race/ethnicity among the study participants.

RESULTS: One-thousand-eight-hundred-seventy-three women were enrolled in the study. There were 280 minority women and 328 women over the age of 70. Women age 70 and older had a 34% increase risk for death when compared to women under 60 (HR = 1.34; 95% CI 1.16-1.54). Non-Hispanic Black women had a 54% decreased risk of death with the addition of maintenance bevacizumab (HR = 0.46, 95% CI:0.26-0.83). Women of Asian descent had more hematologic grade 3 or greater adverse events and a 27% decrease risk of death when compared to non-Hispanic Whites (HR = 0.73; 95% CI: 0.59-0.90).

CONCLUSIONS: Non-Hispanic Black women showed a decreased risk of death with the addition of bevacizumab and patients of Asian ancestry had a lower death rate than all other minority groups, but despite these clinically meaningful improvements there was no statistically significant difference in OS among the groups.

Copyright © 2021. Published by Elsevier Inc.

Keywords: African American women; Asian women; Bevacizumab; Elderly; Minority populations; Ovarian cancer

Publication Types

Grant support